Retrophin (RTRX) Given Daily Coverage Optimism Rating of 0.04

Media stories about Retrophin (NASDAQ:RTRX) have been trending somewhat positive on Saturday, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Retrophin earned a news impact score of 0.04 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.496050448732 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the news stories that may have effected Accern Sentiment’s analysis:

Retrophin (NASDAQ RTRX) traded up 0.93% during midday trading on Friday, hitting $23.86. The stock had a trading volume of 416,535 shares. The company’s market cap is $915.87 million. Retrophin has a 12-month low of $15.55 and a 12-month high of $24.57. The company has a 50-day moving average price of $20.41 and a 200-day moving average price of $19.18.

Retrophin (NASDAQ:RTRX) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.10. The firm had revenue of $38.80 million during the quarter, compared to analyst estimates of $37.36 million. Retrophin had a negative net margin of 48.74% and a negative return on equity of 7.31%. The company’s revenue was up 16.5% on a year-over-year basis. During the same period last year, the company earned $0.07 EPS. Equities analysts anticipate that Retrophin will post ($1.13) EPS for the current year.

A number of equities analysts recently issued reports on the company. TheStreet raised Retrophin from a “d” rating to a “c-” rating in a report on Friday, May 12th. ValuEngine downgraded Retrophin from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Zacks Investment Research downgraded Retrophin from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 3rd. Finally, BidaskClub raised Retrophin from a “hold” rating to a “buy” rating in a report on Wednesday. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $32.25.

WARNING: “Retrophin (RTRX) Given Daily Coverage Optimism Rating of 0.04” was posted by BNB Daily and is the property of of BNB Daily. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.baseball-news-blog.com/2017/08/19/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-retrophin-rtrx-share-price-updated-updated.html.

In other Retrophin news, COO Neil F. Mcfarlane sold 1,378 shares of the company’s stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $22.50, for a total value of $31,005.00. Following the completion of the transaction, the chief operating officer now owns 13,622 shares of the company’s stock, valued at approximately $306,495. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 2.41% of the company’s stock.

About Retrophin

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Insider Buying and Selling by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply